Karo Pharma AB represents values of innovation, integrity, and excellence in the pharmaceutical industry. With a strong corporate philosophy focused on delivering high-quality healthcare solutions, Karo Pharma AB aims to improve patient well-being and enhance their quality of life. The company prioritizes research and development to discover and develop innovative treatments for various medical conditions. Karo Pharma AB is committed to upholding ethical standards, fostering collaborative relationships, and maintaining a sustainable approach in all their endeavors. Through their dedication to excellence, Karo Pharma AB continues to make significant contributions to the healthcare industry.

Karo Pharma AB is primarily present in the Scandinavian region, including Sweden, Norway, Denmark, and Finland.

Karo Pharma AB has achieved several significant milestones. The company successfully acquired Weifa ASA, a leading Norwegian pharmaceutical company, thereby expanding its product portfolio and market presence. Karo Pharma AB also secured a strong financial position by successfully completing a fully underwritten rights issue. This allowed the company to strengthen its strategic focus on development, marketing, and sales of prescription and consumer healthcare products. Additionally, Karo Pharma AB successfully launched new products in key therapeutic areas, further establishing itself as a prominent player in the pharmaceutical industry. These milestones demonstrate the company's commitment to growth, innovation, and providing high-quality healthcare solutions.

Karo Pharma AB, a leading pharmaceutical company, has an impressive history and background. Established in 1987, the company has since grown to become a prominent player in the healthcare industry. Karo Pharma specializes in the development, production, and marketing of effective and high-quality medical products. With a strong focus on innovation and research, the company has built a robust portfolio of prescription and over-the-counter medications. Karo Pharma's commitment to excellence and customer satisfaction has propelled its success in both domestic and international markets. With a rich history of over three decades, Karo Pharma AB continues to make significant contributions to the pharmaceutical sector through its cutting-edge products and unwavering dedication to improving global healthcare.

Karo Pharma AB faces strong competition from various companies in the market. Some of its main competitors include Orifarm Group, Meda AB, and Mylan NV. These companies operate in the same pharmaceutical industry and offer similar products, making the market highly competitive. Karo Pharma AB strives to differentiate itself by focusing on providing innovative and high-quality pharmaceutical solutions. By consistently delivering effective medications and maintaining strong relationships with healthcare professionals and consumers, Karo Pharma AB aims to stay ahead of its rivals in the market.

Karo Pharma AB is primarily active in the pharmaceutical industry.

The business model of Karo Pharma AB focuses on the development, production, and marketing of pharmaceutical products. As a leading specialty pharmaceutical company in Sweden, Karo Pharma AB aims to improve the health and wellbeing of individuals through its diverse portfolio of prescription and over-the-counter medications. The company leverages its strong research and development capabilities to bring innovative and high-quality drugs to market. With a customer-centric approach, Karo Pharma AB strives to address various therapeutic areas and provide effective solutions for patients, healthcare professionals, and partners worldwide.

Det Karo Pharma P/E-forhold er 169,49.

Karo Pharma KUV er 2,84.

AlleAktien Kvalitetsscore for Karo Pharma er 2/10.

Den forventede Karo Pharma omsætning er 4,82 mia. SEK.

Den forventede Karo Pharma indtjening er 80,83 mio. SEK.

Karo Pharma AB is a Swedish pharmaceutical company specializing in the development, manufacturing, and marketing of high-quality branded and OTC products. The company is divided into two main business areas, namely the Consumer Healthcare and Prescription Products divisions. The Consumer Healthcare division includes a wide range of OTC products available in supermarkets, drugstores, and pharmacies. Brands include products such as Tavegyl, Aqualia, Alvedon, Idomin, and Nalox, to name a few. These products cover a variety of indications, including pain and inflammation, allergies, skincare, sleep disorders, and digestive complaints. Karo Pharma's Prescription Products division is dedicated to the development and marketing of prescription drugs and medical devices in Scandinavia. The company works closely with healthcare professionals to meet the needs of patients in various therapeutic areas. Products include medications such as Riftan, Trianal, Ketogan, and Acetylcysteine, as well as medical devices such as inhalable respiratory medications and pain medications. Karo Pharma's business model is based on an "asset-light" approach, where the company acquires high-quality products and brands from third parties to sell them on local and international markets. This allows the company to focus on product development and marketing without the costly manufacturing expenses and building of production facilities. Another key component of Karo Pharma's business model is the continuous investment in research and development. The company has a strong pipeline of new products and technologies that it wants to bring to the market to increase its market presence and growth. Additionally, the company has a strong focus on utilizing innovative technologies to optimize its business processes and increase efficiency and profitability. In conclusion, Karo Pharma's business model is based on the development and marketing of innovative and high-quality drugs and medical devices, as well as branded OTC products, using an asset-light approach. The company aims to continuously grow and strengthen its market presence in national and international markets through research, development, and efficiency optimization.

Karo Pharma udbetaler et udbytte på 0 SEK fordelt over udbetalinger om året.

Udbyttet kan for nuværende ikke beregnes for Karo Pharma, eller selskabet udbetaler ikke udbytte.

ISIN'en for Karo Pharma er SE0007464888.

WKN for Karo Pharma er A14YW4.

Tickeren for Karo Pharma er KARO.ST.

I løbet af de sidste 12 måneder betalte Karo Pharma en dividende på 0,27 SEK . Dette svarer til et dividendeudbytte på omkring 0,45 %. For de kommende 12 måneder vil Karo Pharma sandsynligvis betale en dividende på 0,40 SEK.

Udbytteafkastet for Karo Pharma er i øjeblikket 0,45 %.

Karo Pharma betaler kvartalsvis udbytte. Dette uddeles i månederne .

Karo Pharma betalte udbytte hvert år i løbet af de sidste 4 år.

For de kommende 12 måneder forventes der dividender på 0,40 SEK. Dette svarer til et dividendeafkast på 0,66 %.

Karo Pharma bliver tildelt sektoren 'Sundhed'.

For at modtage det seneste udbytte på Karo Pharma fra den 11.5.2018 på 0,3 SEK, skulle du have haft aktien i din portefølje før ex-datoen den 4.5.2018.

Udbetalingen af det sidste udbytte blev foretaget den 11.5.2018.

I løbet af 2023 udbetalte Karo Pharma 0 SEK i form af dividender.

Udbytterne fra Karo Pharma udbetales i SEK.